Gene Therapy for Hepatocellular Carcinoma—Teaching Old Dogs New Tricks

Afford, Simon C.; Lw, Young

doi:10.1053/jhep.2001.26212

Cited by 8 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adenovirus serotype 5 (Ad5) has become the most widely used system in cancer gene and viro-therapy. One drawback of Ad5 in cancer therapy is its hepatotropism, which is an obvious obstacle for its successful application in liver tumours including cholangiocarcinoma [4,25]. TSPs have been shown to effectively restrict transcriptional activity to tumour cells and thus may be able to prevent replication in normal cells [26].…”

Section: Discussionmentioning

confidence: 99%

“…One method to generate these Conditional Replicating Adenoviral vectors (CRAds) is to restrict the expression of genes essential for viral replication to tumour lesions using tumour specific promoters (TSP). Since Ad5 is hepatotropic it is essential that these TSP are inactive in primary liver cells [4]. This 'liver-off' phenotype of TSP is especially relevant when focusing on treating liver tumours like cholangiocarcinoma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Selection of tumour specific promoters for adenoviral gene therapy of cholangiocarcinoma

Lie-A-Ling

Bakker

Deurholt

et al. 2006

Journal of Hepatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Selection of tumour specific promoters for adenoviral gene therapy of cholangiocarcinoma

Lie-A-Ling

Bakker

Deurholt

et al. 2006

Journal of Hepatology

View full text Add to dashboard Cite

“…9 Percutaneous procedures in the liver typically require a relatively high degree of accuracy, although this has not been definitively quantified. Accuracy may have different significance for individual applications.…”

Section: Applications Requirements and Obstaclesmentioning

confidence: 99%

Assessment of hepatic motion secondary to respiration for computer assisted interventions

Clifford

Banovac

Levy

et al. 2002

Comput. Aided Surg.

View full text Add to dashboard Cite

This article reviews the published efforts to characterize hepatic motion secondary to respiration, with the specific goal of defining the limitations and potential applications of image-guided systems in percutaneous liver interventions (computer assisted interventions). Hepatic motion and deformation due to respiration remain obstacles to applying stereotactic localization techniques to the liver. Respiratory-associated hepatic motion is complex. Nine studies using diagnostic imaging or modeling are reviewed, and their findings are tabulated herein. The significant variations in their findings are discussed, including cranio-caudal translation, anterior-posterior and lateral translation, movement secondary to tissue deformation, and motion with respect to surrounding tissue. Techniques for correcting for hepatic respiratory motion are then described, including gating techniques, modeling approaches, real-time liver tracking, and magnetic tracking technology.

show abstract

A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation

et al. 2006

View full text Add to dashboard Cite

The Model for End-Stage Liver Disease (MELD) score is now used for allocation in liver transplantation (LT) waiting lists, replacing the Child-Turcotte-Pugh (CTP) score. However, there is debate as whether it is superior to CTP score to predict mortality in patients with cirrhosis on the LT waiting list and after LT. We reviewed studies comparing the accuracy of MELD vs. CTP score in transplantation settings. We found that in studies of the LT waiting list (12,532 patients with cirrhosis), only 4 of 11 showed MELD to be superior to CTP in predicting short-term (3-month) mortality. In addition, 2 of 3 studies (n ϭ 1,679) evaluating the changes in MELD score (⌬MELD) showed that ⌬MELD had better prediction for mortality than the baseline MELD score. The impact of MELD on post-LT mortality was assessed in 15 studies (20,456 patients); only 6 (9,522 patients) evaluated the discriminative ability of MELD score using the concordance (c) statistic (the MELD score had always a c-statistic Ͻ 0.70). In 11 studies (19,311 patients), high MELD score indicated poor post-LT mortality for cutoff values of 24-40 points. In re-LT patients, 2 of 4 studies evaluated the discriminative ability of MELD score on post-LT mortality. Finally, several studies have shown that the predictive ability of MELD score increases by adding clinical variables (hepatic encephalopathy, ascites) or laboratory (sodium) parameters. On the basis of the current literature, MELD score does not perform better than the CTP score for patients with cirrhosis on the waiting list and cannot predict post-LT mortality.

show abstract

Gene Therapy for Hepatocellular Carcinoma—Teaching Old Dogs New Tricks

Cited by 8 publications

References 39 publications

Selection of tumour specific promoters for adenoviral gene therapy of cholangiocarcinoma

Selection of tumour specific promoters for adenoviral gene therapy of cholangiocarcinoma

Assessment of hepatic motion secondary to respiration for computer assisted interventions

A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation

Contact Info

Product

Resources

About